David Pearsall Email & Phone Number

Winter Park, FL, US

Mid Atlantic (NC, SC, VA, MD, PA, DC)

- Regional based individual contributor focused on cell therapy demand enablement, financial reimbursement support and key opinion leader development for Kite’s two hematologic CAR T treatments, YESCARTA (axicabtagene ciloleucel) and TECARTUS (brexucabtagene autoleucel).- Geographic responsibility includes 20 authorized in treatment centers in the.

Seattle, Washington, United States

- Sourced and secured placement of the CoreA Therapeutics, Chairman of the Board.- Provide on-going strategic guidance to founding partners, CEO and relevant parties involved with CoreA Therapeutics ADC development plan.

Executed the commercial launch of REZLIDHIA (olutasidinib), a new targeted IDH1 inhibitor therapy for relapsed/refractory mutated IDH1 acute myeloid leukemia. Focused on partnering with AML experts and bone marrow transplant centers within the Southeast and Puerto Rico to help patients beat a rare mutation of acute myeloid leukemia (AML).

• Awarded the 2022 BeiGene Summit Club Award for top performing Division Sales Manager (#1 out of 8 nationally).
• Led a team of Hematology Account Managers within the Southeast selling a BTK inhibitor, BRUKINSA/zanubrutinib, in the B-cell / CLL malignancy therapeutic area.
• Cross-functionally worked with Field Medical Directors, Regional Marketers, Corporate Account Directors, Market Access and senior commercial leadership to drive award winning results.

United States

• New product planning lead for future duvelisib PTCL indication. Developed and maintained a comprehensive business strategy and PTCL brand plan that incorporates cross-functional input from Commercial, Medical Affairs.
• Implemented a unified, strategic framework for national and regional hematology thought leaders (B cell and T cell) ensuring consistency in external engagements and internal communications.

United States

• Maintained accountability of a three-person national KOL Director team measured on national sales performance. Initially in a national individual contributor role prior to successful geographic expansion.

Florida

• Named Esbriet Division Manager of the Year (2015)
• Executed a new orphan drug launch (Esbriet) as division sales leader for a start-up biotech company in the idiopathic pulmonary fibrosis (IPF) market within the FL and PR market.

Southeast

• Won 2013 Spectrum Chairman’s Circle Award (#1 region out of 6).
• Won 2010 Premier Award for finishing first full year of Folotyn launch ranked 1 out of 6 regions.
• Regional sales leadership responsibilities for four buy and bill hematology oncology drugs.Southeast and Puerto Rico.

• National responsibility for the 2007 launch of a new oncology supportive care ultra-orphan repurposed generic drug.
• Responsible for national Key Opinion Leader development.

FL

• Various commercial roles within the following three business units: acute cardiovascular, market access and oncology.
• Positions with increasing responsibility included Southeast Oncology District Manager, Cardiovascular Product Manager, Key Account Group National Manager, Acute Cardiovascular Medical Center Specialist.

Saint Louis, MO

• Positions included National Sales Training Manager (corporate home office based, St. Louis, MO) and Central Florida Sales OR / Critical Care Medical Center Representative.

Orlando, Florida Area

Orlando, Florida Area

Nashville, TN

Door-to-door sales of educational books to families in Horry County, SC and Goldsboro, NC.Earned 50% of 1 year’s college tuition expense during this summer sales position.